NIDDK Central Repository - Interim analysis of a controlled trial of pre-transplant peginterferon alfa-2b/ribavirin (PEG/RBV) to prevent recurrent hepatitis C virus (HCV) infection after liver transplantation (LT) in the adult-to-adult liver transplantation (A2ALL) study

An official website of the United States government

This repository is under review for potential modification in compliance with Administration directives.

NIDDK Central Repository

Publication Information

Public Release Type

Journal

Publication Year

2009

Authors

A2ALL Study Group, Al-Osiami AM, Brown RS, Everhart JE, Everson GT, Gillespie BW, Kulik LM, Lok AS, Saab S, Shiffman ML, Terrault N

Studies

A2ALL

Citation

Everson GT, Terrault N, Lok AS, Brown RS, Saab S, Shiffman ML, Al-Osiami AM, Kulik LM, Gillespie BW, Everhart JE, A2ALL Study Group. Interim analysis of a controlled trial of pre-transplant peginterferon alfa-2b/ribavirin (PEG/RBV) to prevent recurrent hepatitis C virus (HCV) infection after liver transplantation (LT) in the adult-to-adult liver transplantation (A2ALL) study. Hepatology 2009 Sep 23;50(Suppl 4):302A.